| Ytd | 77.63% | |
| 1y | 265.75% |
| Open | 9.34 | Prev Close | 9.49 | Low | 8.96 | High | 9.37 | Mkt Cap | 770.17M |
| Vol | 1.29M | Avg Vol | 1.65M | EPS | -0.88 | P/E | N/A | Forward P/E | -15.83 |
| Beta | 0.11 | Short Ratio | 6.34 | Inst. Own | 78.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-06 | 50-d Avg | 11.67 | 200-d Avg | 9.21 | 1yr Est | 20.27 |
IMMX News
LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We
Immix Biopharma (NASDAQ: IMMX) reported updated clinical data for NXC-201, its investigational CAR T
Immix Biopharma NASDAQ: IMMX reported updated clinical data for NXC-201, its investigational CAR T-c
LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “w
Shares of Immix Biopharma, Inc. (NASDAQ: IMMX - Get Free Report) rose 4.1% during trading on Monday.
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript
Needham analyst Gil Blum maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” o
– 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR
Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and ra
Immix Biopharma, Inc. (NASDAQ: IMMX - Get Free Report)'s stock price hit a new 52-week high during m
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
Morgan Stanley analyst Judah Frommer maintains Immix Biopharma (NASDAQ:IMMX) with a Overweight an
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy a
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
LOS ANGELES--(BUSINESS WIRE)---- $IMMX--IMMX Investors Have Opportunity to Join Immix Biopharma, Inc
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
LOS ANGELES, CA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Boston, Massachusetts--(Newsfile Corp. - July 23, 2026) - Block & Leviton is investigating Immix Bio
Needham analyst Gil Blum initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating an
LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immix Biopharma , (“ Imm
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Immix Bioph
Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating
https://www.statnews.com/2026/07/20/ronald-fischer-rhode-island-fugitive-richard-graydon-biotech/ As
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyl
Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzing
Analysts changed outlook on top Wall Street names. See all changes on our analyst ratings page. Chec
B of A Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy a
Immix Biopharma (IMMX) prices $150M public offering to fund its NXC-201 cell therapy into mid-2028.
The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissi
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)
HC Wainwright & Co. analyst Robert Burns reiterates Immix Biopharma (NASDAQ:IMMX) with a Buy
Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and ra
Citizens analyst Reni J. Benjamin reiterates Immix Biopharma (NASDAQ:IMMX) with a Market Outperfo
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy a
Immix Biopharma (NASDAQ:IMMX) reported quarterly losses of $(0.28) per share which missed the analys
Morgan Stanley analyst Judah Frommer initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a O
Wall Street analysts make changes to top stocks. Check our analyst ratings page for all updates. VAL
Wall Street analysts upgraded and initiated coverage on top stocks, including Redwire, Zions Bancorp
Top analysts change outlook on top names. See all analyst rating changes on Benzinga's analyst r
Citizens analyst Reni Benjamin initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Market
Mizuho analyst Graig Suvannavejh initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Outpe
Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "I
Immix Biopharma Inc (NASDAQ: IMMX) shares are trading lower Monday after the company filed a new she
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy a
NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independe